E2022 Patch Formulation Multiple Dose Phase I Study

Trial Profile

E2022 Patch Formulation Multiple Dose Phase I Study

Phase of Trial: Phase I

Latest Information Update: 30 May 2012

At a glance

  • Drugs Donepezil; Donepezil
  • Indications Alzheimer's disease; Aphasia; Attention deficit and disruptive behaviour disorders; Dementia; Migraine; Mild cognitive impairment; Vascular dementia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 30 May 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 30 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top